Log In
BCIQ
Print this Print this
 

KRN5500

  Manage Alerts
Collapse Summary General Information
Company Kyowa Hakko Kirin Co. Ltd.
DescriptionIV formulation of a semi-synthetic derivative of spicamycin
Molecular Target Not available
Mechanism of Action 
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$27.4M

0

$5.8M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/07/2015

$27.4M

0

$5.8M

Get a free BioCentury trial today